Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Autonomous Technology & Robotics ETF vs BioNTech SE - ADR — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $123.27, while BioNTech SE - ADR trades at $90.89 (market cap $23.14B). The key difference: ARK Autonomous Technology & Robotics ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| ARKQ | BNTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $143.82 | $119.34 |
52-Week Low | $91.86 | $83.89 |
Market Cap | — | $23.14B |
Enterprise Value | — | $6.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKQ trades at $123.99, down 0.57% with a bearish technical signal from moving averages. The ETF focuses on autonomous technology and robotics, benefiting from AI momentum with 57% gains since Q1 2026. Support levels cluster around $122-124 while resistance sits at $126-128. Recent news highlights China's EV targets and humanoid robotics growth projections reaching $200 billion by 2035.
The ETF shows strong momentum in AI and robotics themes but carries premium valuations with a 36x P/E ratio. Key risks include sector concentration and dependency on technological adoption rates. Institutional interest remains strong with $2.7 billion in assets, though technical indicators suggest near-term consolidation pressure.
BNTX trades at $91.49, down 1.6% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $1.14 billion for 2025, with revenue of $2.87 billion, and is undergoing a strategic shift toward oncology, including a $1 billion share buyback and manufacturing site closures affecting 1,860 jobs. Analyst consensus is strongly bullish with a $129.67 price target.
The outlook hinges on BioNTech's transition from COVID-19 vaccine dependency to oncology pipeline success. Opportunities include a strong cash position of $16.78 billion and promising clinical data, but risks involve execution challenges, sustained losses, and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Autonomous Technology & Robotics ETF
ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.
Read more on ARKQ →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
